Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy-Reference-Cited by-同舟云学术

Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy

Published:2014-01-30 Issue:5 Volume:123 Page:632-639
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Mulligan George¹,Lichter David I.¹,Di Bacco Alessandra¹,Blakemore Stephen J.¹,Berger Allison¹,Koenig Erik¹,Bernard Hugues¹,Trepicchio William¹,Li Bin¹,Neuwirth Rachel¹,Chattopadhyay Nibedita¹,Bolen Joseph B.¹,Dorner Andrew J.¹,van de Velde Helgi²,Ricci Deborah³,Jagannath Sundar⁴,Berenson James R.⁵,Richardson Paul G.⁶,Stadtmauer Edward A.⁷,Orlowski Robert Z.⁸,Lonial Sagar⁹,Anderson Kenneth C.⁶,Sonneveld Pieter¹⁰,San Miguel Jesús F.¹¹,Esseltine Dixie-Lee¹,Schu Matthew¹

Affiliation:

1. Takeda Pharmaceuticals International Co., Cambridge, MA;

2. Janssen Research & Development, Division of Janssen Pharmaceutica NV, Beerse, Belgium;

3. Janssen Research and Development, Raritan, NJ;

4. Mount Sinai Hospital, New York, NY;

5. Institute for Myeloma and Bone Cancer Research, West Hollywood, CA;

6. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;

7. University of Pennsylvania Abramson Cancer Center, Philadelphia, PA;

8. Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX;

9. Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA;

10. Department of Hematology, Erasmus Medical Centre, University Hospital Rotterdam, Rotterdam, The Netherlands; and

11. Clinica Universidad de Navarra, Centro de Investigación Medica Aplicada, Pamplona, Spain

Abstract

Key Points A high frequency of RAS/RAF mutations and recurrent mutations in PDGFRA and JAK3 were found in relapsed multiple myeloma patients. Patients with NRAS, but not KRAS, mutation exhibited significantly reduced sensitivity to bortezomib but not high-dose dexamethasone.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/123/5/632/1378351/632.pdf

Reference46 articles.

1. Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2.;Munshi;Blood,2011

2. The impact of genomics on the management of myeloma.;Corre;J Natl Compr Canc Netw,2011

3. Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergroupe Francophone du Myélome.;Decaux;J Clin Oncol,2008

4. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1.;Shaughnessy;Blood,2007

5. Improved survival in multiple myeloma and the impact of novel therapies.;Kumar;Blood,2008

Cited by 104 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clonal competition assays identify fitness signatures in cancer progression and resistance in multiple myeloma;HemaSphere;2024-07

2. Мутации в генах KRAS/NRAS и эффективность индукционной терапии по трехкомпонентным схемам на основе бортезомиба у пациентов с впервые диагностированной множественной миеломой;Clinical Oncohematology;2024-07-01

3. Gene mutations in newly diagnosed multiple myeloma patients detected by next-generation sequencing technology;Cancer Pathogenesis and Therapy;2024-07

4. The Interplay between the DNA Damage Response (DDR) Network and the Mitogen-Activated Protein Kinase (MAPK) Signaling Pathway in Multiple Myeloma;International Journal of Molecular Sciences;2024-06-26

5. Liquid Biopsies as Non-Invasive Tools for Mutation Profiling in Multiple Myeloma: Application Potential, Challenges, and Opportunities;International Journal of Molecular Sciences;2024-05-10